Trial
NCT02245230
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Vanderbilt University
Collaborators
—
Condition
Hypertension
Intervention
Angiotensin (1-7)
Why stopped
We were not able to enroll adequate number of participants that met the inclusion/exclusion criteria, and we run out of funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-09